TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03515226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ITS based training
Description: Training using computerized adaptive training in addition to role play

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Training
Description: Training using didactics and role plays
Study: NCT02576535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic radiosurgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leskell gamma unit
Description: FDA approved device
Study: NCT03490422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Pulpotomy in mature carious permanent teeth
Study: NCT01430156

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: Solution for infusion, this will be given prior to transplantation and again on day 2; the same as active drug.
Study: NCT00970333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FEPPA
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) of \[18F\]-FEPPA followed by serial PET imaging
Study: NCT01313936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metaiodobenzylguanidine (MIBG)
Description: Chemotherapy will be given over 5 days for each course, with a single dose of 131I-MIBG on the second day of irinotecan. A total course will be defined as 42 days, or longer if hematopoietic recovery to eligibility criteria occurs after day 42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metaiodobenzylguanidine (MIBG)
Description: Chemotherapy will be given over 5 days for each course, with a single dose of 131I-MIBG on the second day of irinotecan. A total course will be defined as 42 days, or longer if hematopoietic recovery to eligibility criteria occurs after day 42.
Study: NCT03741179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA-withdrawn group
Description: Patients whith sFlt/PlGF ratio \< 38 at 24+0-27+6 weeks will be randomized into two arms of the trial. Patients allocated in the experimental arm will stop the ASA treatment.
Study: NCT05560997

Intervention type: DIAGNOSTIC_TEST
Intervention: 10-year ASCVD risk estimation
Description: High CVD risk was defined as a history of CVD or a 10-year ASCVD risk ≥10%. The 10-year ASCVD risk estimation was carried out according to 2016 Chinese guidelines for the management of dyslipidemia in adults.

Intervention type: DIAGNOSTIC_TEST
Intervention: 10-year ASCVD risk estimation
Description: High CVD risk was defined as a history of CVD or a 10-year ASCVD risk ≥10%. The 10-year ASCVD risk estimation was carried out according to 2016 Chinese guidelines for the management of dyslipidemia in adults.
Study: NCT03622307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD Therapy Combined with VT Ablation
Description: S-ICD implantation and VT ablation/substrate modification among patients with a secondary prevention indication for an ICD
Study: NCT04417920

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Express implant device
Description: Operative technique in group I (Express implant) was as in group II (trabeculectomy) except with no sclerectomy or peripheral iridectomy , the steps included conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva.~While in group II, Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Express implant device
Description: Operative technique in group I (Express implant) was as in group II (trabeculectomy) except with no sclerectomy or peripheral iridectomy , the steps included conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva.~While in group II, Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock.
Study: NCT01095016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meptin swinghaler
Description: * Dose: 10ug/puff, 2 puffs daily~* Frequency: QD (total 20ug/day)~* Treatment duration: 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berotec
Description: * Dose: 100ug/puff, 2 puffs daily~* Frequency: QD (total 200ug/day)~* Treatment duration: 2 days
Study: NCT02601131

Intervention type: BIOLOGICAL
Intervention: Platelet transfusion

Intervention type: BIOLOGICAL
Intervention: Platelet transfusion

Intervention type: BIOLOGICAL
Intervention: Platelet transfusion

Intervention type: BIOLOGICAL
Intervention: Platelet transfusion
Study: NCT02622542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BMT+TEVAR
Description: These FDA-approved devices will be used for performing TEVAR in the patients randomized to this arm, in addition to the medical therapy to control blood pressure (BMT)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BMT
Description: Optimal medical therapy will be administered to the patients randomized to this arm, involving but not limited to, beta-blockers, etc., to control the blood pressure and pain for stabilizing the patient upon presentation.
Study: NCT04326907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous centrifuged adipose tissue (CAT) injection after anal fistulectomy
Description: Collection and injection of autologous adipose tissue in complex anal fistulas in one surgical step under locoregional or general anesthesia.
Study: NCT01808287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN 3 Transcatheter Heart Valve
Description: The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (intermediate or higher operable risk) with severe aortic stenosis requiring aortic valve replacement (AVR).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN 3 Transcatheter Heart Valve
Description: The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (intermediate or higher operable risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
Study: NCT02424747

Intervention type: OTHER
Intervention: Acute Kidney Injury
Description: We will identify and observe exposure to Acute Kidney Injury during Intensive Care admission.
Study: NCT03966001

Intervention type: OTHER
Intervention: Transvaginal sonography at six months after cesarean section
Description: In the sixth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.

Intervention type: OTHER
Intervention: Transvaginal sonography at six months after cesarean section
Description: In the sixth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.

Intervention type: OTHER
Intervention: Transvaginal sonography at twelve months after cesarean section
Description: In the twelfth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.

Intervention type: OTHER
Intervention: Transvaginal sonography at twelve months after cesarean section
Description: In the twelfth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
Study: NCT01509430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise Training
Description: 12 weeks of Progressive Resistance Exercise Training followed by 12 weeks of self chosen training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise Training
Description: 12 weeks of self chosen training followed by 12 weeks of progressive resistance exercise training
Study: NCT00798239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
Description: 150 micorgrams/cc BVF

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iliac crest autograft
Description: autograft

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
Description: 750 micrograms/cc BVF
Study: NCT04509674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04007237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: shampoo with different composition
Description: To reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: shampoo with different composition
Description: To reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor.
Study: NCT04108845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15-Valent Pneumococcal Conjugate Vaccine
Description: 3/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
Study: NCT01076062

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induction of Labor
Description: If cervical foley bulb placement is possible, the foley bulb will remain in place until either spontaneously removed or after 12 hrs, whichever is earlier. If placement is not possible, cervical ripening with misoprostol 25 micrograms (mcg) per vagina every 4 hrs (max of 4 total doses) will be initiated. Cervical examination will occur every 4 hr. Repeat doses of misoprostol will be given only if foley bulb placement is not possible and/or if palpably firm uterine contractions are less than 6 in 10 min in consecutive 10 min intervals. Once placement of a cervical foley bulb can be performed, oxytocin administration will begin at 2 mIU/min and increasing by 2 mIU/min every 20 min to ensure adequate contractions (maximum oxytocin infusion rate 36 mIU/min). Adequate contractions will be defined as 7 contractions in 15 min in consecutive 15 min intervals that palpate moderate to firm. Oxytocin infusion will begin not earlier than 4 hrs after the last misoprostol dose (if given).
Study: NCT00539383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG1005
Description: IV infusion once every 21 days
Study: NCT01839591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: catheter ALAIR
Description: Catheter ALAIR Radiofrequency 65°
Study: NCT03517930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
Study: NCT02325466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: ticagrelor 90 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor Placebo
Study: NCT03517930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
Study: NCT03555981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Kangaroo Mother Care
Description: Continuous skin-to-skin contact between baby and mother/caregiver started within 24h of hospital admission

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Incubator or radiant heater care until stable, off oxygen and \>24h of admission, at which point will start intermittent or continuous kangaroo mother care
Study: NCT04262505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Group
Description: Participants will be advised to follow a traditional Mediterranean diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating Group
Description: Participants will be advised to follow the Healthy Eating Guidelines in Ireland
Study: NCT02059460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01930747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium
Description: measure effect on laparoscopic workspace

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 1 MAC sevoflurane inhalation is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanyl
Description: remifentanyl is given in infusion
Study: NCT03973840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate
Description: dose was given orally and allowed to reach steady state
Study: NCT01912651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cephalexin
Description: This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week). Patients will be followed up within 2 to 6 weeks of surgery and outcome measures assessed. Patients will, again, be seen at 6 months and 1 year post-operatively for outcome assessment.
Study: NCT02875860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GoldBal2 detachable balloon
Description: Placement of the balloon using the plug/unplug method.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baltaccidbpe100 Delivery Catheter
Description: The catheter assists with implanting the balloon in the plug/unplug method.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized postnatal care
Description: After birth, the babies will receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website. For detailed description on this please visit https://www.karger.com/Article/Abstract/320622

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized postnatal care
Description: After birth, the babies will receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website. For detailed description on this please visit https://www.karger.com/Article/Abstract/320622
Study: NCT01835067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Single intravitreal injection of 500 micrograms ranibizumab in 0.05mls

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ranibizumab
Description: Single intravitreal injection of 500 micrograms ranibizumab in 0.05mls

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Single intravitreal injection of 500 micrograms ranibizumab in 0.05mls

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Single intravitreal injection of 500 micrograms ranibizumab in 0.05mls

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C3F8 Gas
Description: Single intravitreal injection of 0.3 mls C3F8
Study: NCT03496558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Variability of the lipid profile in pregnant women
Description: The women participants will be divided into two groups. Group 1 comprised of healthy women and group 2 by pregnant women with a history of risk. A personal, family history and a detailed medical history will be taken in each group. We will proceed to see all possible variables that influence the level of biomarkers (lipids and prolactin).~At least 60 healthy pregnant women and 60 pregnant women with a history of risk (20 for each risk) x 2 series (three years) will be tried, a total of 240-300 women to whom 5 analytical tests would have to be performed.
Study: NCT04720794

Intervention type: DEVICE
Group type: OTHER
Intervention: Lucira COVID-19 All-In-One test kit
Description: The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider
Study: NCT03352713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laddr
Description: Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences.
Study: NCT00716170

Intervention type: BIOLOGICAL
Intervention: Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)
Description: Day A: Oral glucose tolerance test (50g glucose)~Day B: Isoglycemic intravenous (iv) glucose infusion~Day C: Isoglycemic iv glucose infusion + iv GIP infusion (0-20 min: 4 pmol/kg body weight/min; 20-50 min: 2 pmol/kg body weight/min)~Day D: Isoglycemic iv glucose infusion + iv GLP-1 infusion (0-20 min: 0,6 pmol/kg body weight/min; 20-50 min: 0,3 pmol/kg body weight/min)~Day E: Isoglycemic iv glucose infusion + iv GLP-2 infusion (0-20 min: 1 pmol/kg body weight/min; 20-50 min: 0,5 pmol/kg body wight/min)~Day F: Isoglycemic iv glucose infusion + iv infusion of GIP, GLP-1 and GLP-2 in doses as Day C, D and E.
Study: NCT01413659

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Symbiotic
Description: Oral symbiotic every 8 h since 2 days before operation; Symbiotic resumes postoperatively on day +2 until day +4 for a total of 4 d of treatment (12 doses).
Study: NCT00536120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG00002 (natalizumab)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: keyhole limpet hemocyanin (KLH)
Description: KLH 1 mg administered subcutaneously (SC) in accordance with the Immucothel investigator's brochure.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: keyhole limpet hemocyanin (KLH)
Description: KLH 1 mg administered subcutaneously (SC) in accordance with the Immucothel investigator's brochure.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus diphtheria toxoid vaccine (Td)
Description: Td administered in accordance with the manufacturer's prescribing information.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: tetanus diphtheria toxoid vaccine (Td)
Description: Td administered in accordance with the manufacturer's prescribing information.
Study: NCT02777541

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Resumption of feeding 3 hours after PEG placement
Description: The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Resumption of feeding 8 hours after PEG placement
Description: The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
Study: NCT02032836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lloprost(Ventavis,BAYQ6252, 20 µg/mL)
Description: 20 µg/mL iloprost nebulizer solution, inhaled with FOX nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lloprost(Ventavis,BAYQ6252, 20 µg/mL)
Description: 20 µg/mL iloprost nebulizer solution, inhaled with FOX nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lloprost(Ventavis,BAYQ6252, 10 µg/mL)
Description: 10 µg/mL iloprost nebulizer solution, inhaled with I-Neb nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lloprost(Ventavis,BAYQ6252, 10 µg/mL)
Description: 10 µg/mL iloprost nebulizer solution, inhaled with I-Neb nebulizer